Optimized subunit vaccine protects against experimental leishmaniasis

Vaccine

Volumn 27, Issue 50, 2009, Pages 7036-7045

  Bertholet, Sylvie ^a   Goto, Yasuyuki ^a   Carter, Lauren ^a   Bhatia, Ajay ^a   Howard, Randall F ^a   Carter, Darrick ^a   Coler, Rhea N ^a   Vedvick, Thomas S ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Leishmania; MPL; vaccination

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LEISHMANIA VACCINE; MPL; PHOSPHORYL LIPID A; PROTEIN LEISH 110F; PROTEIN LEITH 111F; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-2; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SUBUNIT;

EID: 70350569335     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.066     Document Type: Article

References (58)

1. Tripathi P., Singh V., and Naik S. Immune response to Leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 51 2 (2007) 229-242
2. Reiner S.L., and Locksley R.M. The regulation of immunity to Leishmania major. Annu Rev Immunol 13 (1995) 151-177
3. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 11 (2002) 845-858
4. Scott P., Artis D., Uzonna J., and Zaph C. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201 (2004) 318-338
5. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168 April (15) (2002) 3992-4000
6. + T cells. J Exp Med 199 June (11) (2004) 1559-1566
7. Muller I. Role of T cell subsets during the recall of immunologic memory to Leishmania major. Eur J Immunol 22 12 (1992) 3063-3069
8. + T cells. Infect Immun 61 9 (1993) 3730-3738
9. + T cells following secondary infection of mice immune to Leishmania major. Infect Immun 62 6 (1994) 2575-2581
10. Titus R.G., Milon G., Marchal G., Vassalli P., Cerottini J.C., and Louis J.A. Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur J Immunol 17 10 (1987) 1429-1433
11. Launois P., Louis J.A., and Milon G. The fate and persistence of Leishmania major in mice of different genetic backgrounds: an example of exploitation of the immune system by intracellular parasites. Parasitology 115 Suppl. (1997) S25-S32
12. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 5 (2005) 244-249
13. Kedzierski L., Zhu Y., and Handman E. Leishmania vaccines: progress and problems. Parasitology 133 Suppl. (2006) S87-S112
14. Sukumaran B., and Madhubala R. Leishmaniasis: current status of vaccine development. Curr Mol Med 4 6 (2004) 667-679
15. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 9 (2004) 1505-1517
16. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20 September (27-28) (2002) 3292-3303
17. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70 8 (2002) 4215-4225
18. + T cells. Infect Immun 75 9 (2007) 4648-4654
19. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 November (45) (2005) 5245-5251
20. Moreno J., Nieto J., Masina S., Canavate C., Cruz I., Chicharro C., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25 July (29) (2007) 5290-5300
21. Miret J., Nascimento E., Sampaio W., Franca J.C., Fujiwara R.T., Vale A., et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26 March (12) (2008) 1585-1594
22. Vedvick T.S., Carter L., Garner M., Goto Y., Bertholet S., Reed S., et al. An improved manufacturing process for a recombinant polyprotein vaccine. Biopharm Int January (Suppl.) (2008) 14-22
23. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 May (Suppl. 3) (2002) S56-64
24. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12 4 (2000) 456-463
25. Schijns V.E., and Tangeras A. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches. Dev Biol (Basel) 121 (2005) 127-134
26. Becker C.E., and O'Neill L.A. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol 29 3 (2007) 239-248
27. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 89 January (1) (1992) 358-362
28. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16 7 (1998) 708-714
29. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., et al. Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert opin Biol Ther 4 7 (2004) 1129-1138
30. Becker R., Eichler M.K., Jennemann R., and Bertalanffy H. Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate. Br J Neurosurg 16 3 (2002) 269-275
31. Bienzle U., Gunther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38 4 (2003) 811-819
32. Desombere I., Van der Wielen M., Van Damme P., Stoffel M., De Clercq N., Goilav C., et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 20 June (19-20) (2002) 2597-2602
33. Drachenberg K.J., Heinzkill M., Urban E., and Woroniecki S.R. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 31 September-October (5) (2003) 270-277
34. Drachenberg K.J., Wheeler A.W., Stuebner P., and Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56 6 (2001) 498-505
35. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., and Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vacc 2 2 (2003) 219-229
36. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., Quetz Jda S., Martins Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36 September-December (5-6) (2005) 827-838
37. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 November (31-32) (2002) 3644-3649
38. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39 1 (2003) 70-77
39. McCormack S., Tilzey A., Carmichael A., Gotch F., Kepple J., Newberry A., et al. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18 January (13) (2000) 1166-1177
40. Mothes N., Heinzkill M., Drachenberg K.J., Sperr W.R., Krauth M.T., Majlesi Y., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33 9 (2003) 1198-1208
41. Neidhart J., Allen K.O., Barlow D.L., Carpenter M., Shaw D.R., Triozzi P.L., et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 22 January (5-6) (2004) 773-780
42. Stanberry L.R. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 Suppl. 3 (2004) 161A-169A
43. Vandepapeliere P., Rehermann B., Koutsoukos M., Moris P., Garcon N., Wettendorff M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23 April (20) (2005) 2591-2601
44. Vantomme V., Dantinne C., Amrani N., Permanne P., Gheysen D., Bruck C., et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27 March-April (2) (2004) 124-135
45. Vernacchio L., Bernstein H., Pelton S., Allen C., MacDonald K., Dunn J., et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 20 November (31-32) (2002) 3658-3667
46. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers T, Poshusta GR, et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B; 2009 Aug 20 [Epub ahead of print].
47. + T cells by Leishmania major-infected dendritic cells. Infect Immun 73 10 (2005) 6620-6628
48. Goto Y., Bogatzki L.Y., Bertholet S., Coler R.N., and Reed S.G. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25 October (42) (2007) 7450-7458
49. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 7 (1998) 3279-3289
50. Webb J.R., Campos-Neto A., Skeiky Y.A., and Reed S.G. Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol Biochem Parasitol 89 2 (1997) 179-193
51. Webb J.R., Kaufmann D., Campos-Neto A., and Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 157 December (11) (1996) 5034-5041
52. Skeiky Y.A., Guderian J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M., et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 181 April (4) (1995) 1527-1537
53. Reed S.G., and Campos-Neto A. Vaccines for parasitic and bacterial diseases. Curr Opin Immunol 15 4 (2003) 456-460
54. Aagaard C., Hoang T.T., Izzo A., Billeskov R., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PloS one 4 6 (2009) e5930
55. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G., Vedvick T.S., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27 23 (2009) 3063-3071
56. Khoshgoo N., Zahedifard F., Azizi H., Taslimi Y., Alonso M.J., and Rafati S. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine 26 October (46) (2008) 5822-5829
57. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 7 (2007) 843-850
58. ® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27 43 (2009) 5956-5963